Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 49 of the 156 sources its claims cite were checked for support.
Abstract
Many guidelines recommend deprescribing benzodiazepines and z-drugs in most long-term users. Due to physical dependence in those using medication as prescribed (distinct from addiction), discontinuation can be difficult and is often unsuccessful, as withdrawal symptoms can be severe and long-lasting, especially after long-term use. There is a lack of clarity on how to taper patients in a tolerable manner that minimizes discomfort. Current guidelines vary with some suggesting linear reductions (e.g. 1 mg every 1-4 weeks) and some proportionate reductions (e.g. 5%-10% of the most recent dose per month, with smaller reductions as the dose decreases). The shape of the relationship between dose of benzodiazepine and activity at gamma-aminobutyric acid-A (GABA-A) receptors is hyperbolic: steeply inclining at low doses, flattening at higher doses. Consequently, linear dose reductions produce increasingly large changes in receptor occupancy, predicting escalating withdrawal effects, while hyperbolic or proportionate dose reductions produce linear reductions in pharmacological effect. Slower tapering (over months and years) may be more successful than tapering over days or weeks. In practice, rate of tapering should be adjusted according to severity of withdrawal effects. Final doses for some people will need to be very small (equivalent to as little as 0.2 mg of diazepam, or less) so that the last 'step down' to zero is not larger than prior tolerated reductions in terms of pharmacological effects. Liquids or compounded formulations of medication can be helpful at low doses to make small reductions. Guidelines should recommend hyperbolic tapering while awaiting randomized trials comparing linear with hyperbolic tapering.
Overview
CoChat Summary
TL;DR
This narrative review argues that benzodiazepine and z-drug tapering should follow hyperbolic/proportionate dose reductions because the dose–GABA-A occupancy relationship is hyperbolic, so linear reductions produce increasingly large pharmacological effects and likely worsening withdrawal. It recommends slow, symptom-guided tapering with very small final doses, while noting that randomized trials comparing linear and hyperbolic tapering are still lacking.
Key findings
- Benzodiazepine dose and GABA-A occupancy are hyperbolically related: reducing diazepam by fixed 12.5 mg steps from 50 mg produces progressively larger occupancy drops—6.6 percentage points (50 to 37.5 mg), 10.0 p.p. (37.5 to 25 mg), 16.7 p.p. (25 to 12.5 mg), and 33.6 p.p. (12.5 to 0 mg). At low doses, 5 to 0 mg changes occupancy by 16.8 p.p., exceeding the 13.3 p.p. change from 100 to 50 mg.
- Linear tapering is often unsuccessful: one trial found 90% of linearly tapered patients experienced withdrawal symptoms, with 32% on long half-life benzodiazepines and 42% on short half-life benzodiazepines unable to cease medication; only 36% successfully stopped after a 4-week taper at 15-month follow-up. A systematic review of 35 studies found best results with a 10-week taper, though 31% still could not stop.
- Hyperbolic/proportionate tapering—approximately 5%–10% of the most recent dose every 1–2 weeks—produces roughly linear reductions in GABA-A occupancy (about 1–2 percentage points per step) and is recommended over linear tapering. Final doses may need to be very small, equivalent to as little as 0.2 mg diazepam or less, so the last step to zero is not larger than previously tolerated reductions.
- Adding psychological support to tapering increased cessation rates (OR 1.82) with sustained benefit at follow-up (OR 1.88), whereas gradual tapering alone had a larger effect versus routine care (OR 6); no medication is approved for benzodiazepine withdrawal, and the ASAM panel found no single medication with enough data to recommend.
Methods
- Narrative review of benzodiazepine withdrawal syndrome and commonly used tapering guidance from UK and US authorities, plus review of basic benzodiazepine pharmacology and withdrawal neurobiology.
- Targeted literature searches on PubMed and Google Scholar for relevant domains; principles for tapering were developed from this understanding.
- Focused on patients taking benzodiazepines as prescribed without benzodiazepine use disorder, stated to account for 98% of benzodiazepine users; management of addiction was outside scope.
Limitations
- The paper states that PET imaging data used to model the dose–occupancy curve come from non-human primates rather than humans, represent single doses and population averages, and obscure inter-individual variability in receptor sensitivity, binding affinity, and pharmacodynamic response.
- The paper states that no empirical studies have directly tested linear versus hyperbolic tapering; the recommendation remains a biologically plausible inference from receptor theory and clinical experience.
- The paper states that modeling assumes steady-state pharmacokinetics and linear elimination, which may be disrupted by illness, polypharmacy, or metabolic variability; evident from the text, this is a narrative review without a randomized trial or systematic meta-analysis comparing tapering strategies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
35 Valid · 5 Not valid · 57 Not checked · 26 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Guidelines universally recommend tapering benzodiazepines, yet there is no definitive method, and most advice is based on expert consensus rather than empirical evidence or pharmacological principles, resulting in conflicting advice (Brunner et al., 2025; Pollmann, Murphy, Bergman, & Gardner, 2015).”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
What the sources say
- Partly supportedcites Brunner et al., 2025 sourceExperimental — accuracy not yet measured
The Summary of Recommendations says tapering is indicated for patients likely to be physically dependent when the risks of continued benzodiazepine use outweigh the benefits. The Tapering Process section says most existing guidance emphasizes gradual dose reductions for dependent patients, not that guidelines universally recommend tapering for all patients. (LLM, conf=0.88)
- Partly supportedcites Pollmann, Murphy, Bergman, & Gardner, 2015 sourceExperimental — accuracy not yet measured
In Results > Deprescribing strategies (page unavailable), the review says that most review articles and clinical practice guidelines—60 of 65 (92%)—recommended gradual dose reduction. This supports tapering as a common recommendation, but the combined figure does not establish that guidelines universally recommend it. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Severe withdrawal from physical dependence alone does not imply addiction.”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Methods
What the sources say
- Supportedcites Horowitz & Taylor, 2023 source
The paper's central argument is exactly this separation: it states that 'dependence is not the same as addiction' and that withdrawal effects occur irrespective of whether drugs are taken as prescribed or misused, with tolerance and withdrawal 'not necessarily indicate[ing] the presence of an addiction'. Severity is covered too: the copy notes that 'when these withdrawal symptoms are intolerable, patients can be unable to stop these medications, even when they desire to do so', while still classing such drugs (e.g. antidepressants) as dependence-forming but not addictive, and warns that people struggling with withdrawal 'can be accused of addiction or misuse'. Thus severe withdrawal from physical dependence alone does not imply addiction is the source's own thesis, not merely a quoted DSM-5 line it reproduces. (LLM, conf=0.88)
- Partly supportedcites O’Brien, 2011 sourceExperimental — accuracy not yet measured
In the Abstract (page unavailable), the paper distinguishes physical dependence and withdrawal from addiction, which it describes as compulsive drug-seeking. It also says withdrawal symptoms alone do not count toward a substance-use diagnosis during appropriate medical treatment. It does not specifically address severe withdrawal, so that qualifier is not directly supported. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only 36% of patients were able to successfully stop their benzodiazepine in a similar trial with a 4-week taper at 15-month follow-up (Voshaar et al., 2003).”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Existing evidence for linear versus hyperbolic tapering
What the sources say
- Partly supportedcites Voshaar et al., 2003 sourceExperimental — accuracy not yet measured
The Intervention section describes a four-week taper, so that part matches. But Table 2 reports outcomes at three months, not 15 months: successful discontinuation in the taper-only group was 51% of the whole assigned group or 62% of those who completed follow-up, not 36%. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clinical studies have reported that linear tapering is unsuccessful for a significant proportion of patients.”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Existing evidence for linear versus hyperbolic tapering
What the sources say
- Not matchedcites Schweizer et al., 1990
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Voshaar et al., 2003 source
The Intervention section describes a scheduled reduction of the daily diazepam dose by 25% each week over four weeks, with an option to split the final step. The Results report successful discontinuation in 62% of the tapering-only group, meaning a substantial proportion did not discontinue. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“A survey of specialized deprescribing clinics around the world report using hyperbolic tapering as their main approach to safely stopping psychiatric drugs, including benzodiazepines (Cooper et al., 2023).”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Existing evidence for linear versus hyperbolic tapering
What the sources say
- Supportedcites Cooper et al., 2023 source
The Results (Descriptions of services and common characteristics; page unavailable) describe gradual, broadly hyperbolic tapering as a commonly reported practice, while specifying that some services used broadly hyperbolic strategies. The same section says most services worked with a range of psychotropic medications, including benzodiazepines; the Discussion identifies this as an international survey of 13 services. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
77 more claims · 22 with their cited sources checked
Create a free account to see all 123 claims and to verify the 2 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“clonazepam (0.125 mg, 7.8% occupancy)”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Clonazepam | 0.25 mg | 18–50 | 0.5 mg, 2 mg | 0.5 mg/5 mL,2 mg/5 mL | 9.2b |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“temazepam (2.5 mg, 5.3% occupancy)”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Temazepam | 10 mg | 8–22 | 10 mg, 20 mg | 10 mg/5 mL | 4.8b |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Lorazepam | 0.5 mg | 10–20 | 0.5 g, 1 mg, 2.5 mg | 1 mg/mL | 4.8b |”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“lorazepam (0.125 mg, 5.3% GABA-A occupancy)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Implementation in clinical practice > Small dose formulations
“lorazepam (0.125 mg, 5.3% GABA-A occupancy)”
§ Pharmacological principles for safe benzodiazepine and Z-drug dose reduction > Introduction
“| Lorazepam | 0.5 mg | 10–20 | 0.5 g, 1 mg, 2.5 mg | 1 mg/mL | 4.8b |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“A systematic review of 35 studies found the best results with a 10-week taper, though 31% still could not stop (Cantopher, Olivieri, Cleave, & Edwards, 1990; Denis, Fatseas, Lavie, & Auriacombe, 2005).”
Cited work 10.1002/14651858.cd005194 · retracted 2013-06-18 · notice 10.1002/14651858.cd005194.pub3 · this paper published 2026
Citations
Cites
1 retracted
Denis, C., Fatséas, M., Lavie, E., & Auriacombe, M. (2005) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194 · Cited by 3 · cited 2×
“A systematic review of 35 studies found the best results with a 10-week taper, though 31% still could not stop (Cantopher, Olivieri, Cleave, & Edwards, 1990; Denis, Fatseas, Lavie, & Auriacombe, 2005).”
RetractedA Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · cited 2×
“This table, based on the E max equation of best fit derived from the data in Brouillet et al. (1991), after conversion to human equivalent dosage (Nair & Jacob, 2016”
InfluentialBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630 · cited 1×
“While the benefits of benzodiazepines in acute syndromes are unchallenged for psychiatric indications (Krystal et al., 2003; Roth et al., 2005), the dangers of long-term prescribing are widely accepted (Olfson, King, & Schoenbaum, 2015).”
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 6×
“Reduced GABA transmission allows increased excitatory activity, as neurotransmitters like glutamate act with less opposition (Ashton, 2005), perhaps explaining symptoms such as panic, anxiety, tachycardia, diaphoresis, and typical of excitatory states.”
InfluentialThe amnesic action of benzodiazepines in man
Lister, R. G. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90034-x · Cited by 448 · cited 1×
“Longer-term use is associated with a number of physical and cognitive risks, including physical dependence, tolerance, loss of efficacy, falls, and fractures ( Donnelly et al., 2017) and memory disturbance (Lister, 1985).”
Kapur, J., & Macdonald, R. L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07532.1997 · Cited by 427 · cited 1×
“Seizure threshold shows a hyperbolic relationship to dose in zebrafish (Gupta, Kho-bragade, & Shingatgeri, 2014), rats (Kapur & Macdonald, 1997), and non-human primates (Bottlaender et al., 1994) (Figure 3b).”
Benzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337
Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis
Barker, M. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00096-9 · Cited by 307 · cited 1×
“Withdrawal symptoms can last for many months and sometimes years (Ashton, 1987, 2005; Barker, Greenwood, Jackson, & Crowe, 2004; Higgitt, Fonagy, Toone, & Shine, 1990), and meta-analysis shows cognitive effects after long-term use lasting over six months (Barker et al., 2004).”
Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies
Markota, M., Rummans, T. A., Bostwick, J. M., & Lapid, M. I. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.07.024 · Cited by 307
(2004) · PubMed · Cited by 296
Addiction and dependence in DSM‐V
O'Brien, C. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03144.x · Cited by 292 · cited 1×
“…physical dependence – neuroadaptation causing withdrawal on reduction – from addiction, which also involves psychological dependence (including compulsion, craving, and other behavioral and cognitive components not seen in physical dependence alone) (Horowitz & Taylor, 2023; O ’ Brien, 2011).”
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · cited 3×
“The benzodiazepine withdrawal syndrome (Brunner et al., 2025; Cosci & Chouinard, 2020; Ng et al., 2018; Sokya, 2017) Psychological Medicine psychiatric disorder, thereby perpetuating unnecessary long-term treatment (Markota, Rummans, Bostwick, & Lapid, 2016; Moore, Pariente, & Begaud, 2015).”
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253 · cited 1×
“Normal-dose physical dependence was observed from the 1960s leading to their restriction by the FDA in 1975 (Guina & Merrill, 2018; Lader, 1991).”
Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.
(2018) · Europe PMC (PubMed Central) · Cited by 250
Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 1×
“There is mixed evidence about the connection between benzodiazepine use and increased risk of dementia (De Gage et al., 2014; Friesen et al., 2025; Gray et al., 2016) and increased mortality (Ng, Le Couteur, & Hilmer, 2018; Patorno et al., 2017).”
The clinical and forensic toxicology of Z-drugs
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0292-0 · Cited by 230 · cited 1×
“Benzodiazepines and z-drugs are positive allosteric modulators of the GABA-A receptor, producing their clinical effects by enhancing the effect of the neurotransmitter GABA at the GABA-A receptor (Cheng, Wallace, Ponteri, & Tuli, 2018; Gunja, 2013).”
ROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230 · cited 1×
“While the benefits of benzodiazepines in acute syndromes are unchallenged for psychiatric indications (Krystal et al., 2003; Roth et al., 2005), the dangers of long-term prescribing are widely accepted (Olfson, King, & Schoenbaum, 2015).”
Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174730 · Cited by 225 · cited 1×
“Longer-term use is associated with a number of physical and cognitive risks, including physical dependence, tolerance, loss of efficacy, falls, and fractures ( Donnelly et al., 2017) and memory disturbance (Lister, 1985).”
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212 · cited 1×
“Rapid withdrawal produces more severe symptoms and higher dropout rates than slower tapering (Morin, Bélanger, Bastien, & Vallières, 2005; Parr et al., 2008), while gradual reduction yields better outcomes (Parr et al., 2008).”
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212 · cited 1×
“Anxiolytic effects increase hyperbolically in pigeons (Kleven & Koek, 1999), rats (Dubinsky et al., 2002), and non-human primates (Rowlett et al., 2005) (Figure 3c).”
Long-term Therapeutic Use of Benzodiazepines: II. Effects of Gradual Taper
Schweizer, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220024003 · Cited by 191
(2003) · Europe PMC (PubMed Central) · Cited by 176
A comparison of seven methods for fitting the Michaelis-Menten equation
Atkins, G. L., & Nimmo, I. A. (1975) · Biochemical Journal · doi:10.1042/bj1490775 · Cited by 174 · cited 1×
“PET scanning, using the radioligand [ 11 C]flumazenil in non-human primates (Figure 2a), allows visualization of this hyperbolic relationship (Atkins & Nimmo, 1975; Brouillet et al., 1991; Holford, 2018).”
Benzodiazepines and Development of Delirium in Critically Ill Children: Estimating the Causal Effect
Mody, K., Kaur, S., Mauer, E. A., Gerber, L. M., Greenwald, B. M., Silver, G., & Traube, C. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003194 · Cited by 161 · cited 1×
“…occur between benzodiazepine dose and saccadic slowing/sedation (Hommer et al., 1986), zolpidem ’ s effects on sleep (Merlotti et al., 1989) (Figure 3d), diazepam ’ s impact on cortisol and growth hormone (Hommer et al., 1986) and delirium risk in critically ill children (Mody et al., 2018).”
Benzodiazepine withdrawal: outcome in 50 patients
ASHTON, H. (1987) · British Journal of Addiction · doi:10.1111/j.1360-0443.1987.tb01529.x · Cited by 160 · cited 2×
“Withdrawal symptoms can last for many months and sometimes years (Ashton, 1987, 2005; Barker, Greenwood, Jackson, & Crowe, 2004; Higgitt, Fonagy, Toone, & Shine, 1990), and meta-analysis shows cognitive effects after long-term use lasting over six months (Barker et al., 2004).”
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154 · cited 1×
“Only 36% of patients were able to successfully stop their benzodiazepine in a similar trial with a 4-week taper at 15-month follow-up (Voshaar et al., 2003).”
Psychosocial interventions for benzodiazepine harmful use, abuse or dependence
Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009652.pub2 · Cited by 142 · cited 1×
“CBT does not improve long-term outcomes (Darker et al., 2015) likely because withdrawal is driven by physiological adaptations requiring gradual reduction.”
History of benzodiazepine dependence
LADER, M. H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90027-8 · Cited by 129 · cited 4×
“…for benzodiazepine withdrawal (All Wales Medicines Strategy Group, 2016; Ford et al., n.d.; Horowitz & Taylor, 2024; Teboul & Chouinard, 1990, 1991) (cid:129) Drugdose,frequency,anddurationofuse – frequent,long-term,high-dose users at increased risk (cid:129) History of exposure to numerous…”
InfluentialPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Ng, B. J., Le Couteur, D. G., & Hilmer, S. N. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0544-4 · Cited by 118 · cited 1×
“The benzodiazepine withdrawal syndrome (Brunner et al., 2025; Cosci & Chouinard, 2020; Ng et al., 2018; Sokya, 2017) Psychological Medicine psychiatric disorder, thereby perpetuating unnecessary long-term treatment (Markota, Rummans, Bostwick, & Lapid, 2016; Moore, Pariente, & Begaud, 2015).”
Blanco, C., Han, B., Jones, C. M., Johnson, K., & Compton, W. M. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12174 · Cited by 117
Benzodiazepine Sensitivity in Normal Human Subjects
Hommer, D. W. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800060032005 · Cited by 114 · cited 2×
“…occur between benzodiazepine dose and saccadic slowing/sedation (Hommer et al., 1986), zolpidem ’ s effects on sleep (Merlotti et al., 1989) (Figure 3d), diazepam ’ s impact on cortisol and growth hormone (Hommer et al., 1986) and delirium risk in critically ill children (Mody et al., 2018).”
Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review
Pollmann, A. S., Murphy, A. L., Bergman, J. C., & Gardner, D. M. (2015) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-015-0019-8 · Cited by 114 · cited 5×
“Guidelines universally recommend tapering benzodiazepines, yet there is no definitive method, and most advice is based on expert consensus rather than empirical evidence or pharmacological principles, resulting in conflicting advice (Brunner et al., 2025; Pollmann, Murphy, Bergman, & Gardner, 2015).”
InfluentialLong-term benzodiazepine and Z-drugs use in England: a survey of general practice
Davies, J., Rae, T. C., & Montagu, L. (2017) · British Journal of General Practice · doi:10.3399/bjgp17x691865 · Cited by 99
Benzodiazepines and risk of all cause mortality in adults: cohort study
Patorno, E., Glynn, R. J., Levin, R., Lee, M. P., & Huybrechts, K. F. (2017) · BMJ · doi:10.1136/bmj.j2941 · Cited by 98 · cited 1×
“There is mixed evidence about the connection between benzodiazepine use and increased risk of dementia (De Gage et al., 2014; Friesen et al., 2025; Gray et al., 2016) and increased mortality (Ng, Le Couteur, & Hilmer, 2018; Patorno et al., 2017).”
Morin, C. M., Bélanger, L., Bastien, C., & Vallières, A. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2003.12.002 · Cited by 91 · cited 1×
“Rapid withdrawal produces more severe symptoms and higher dropout rates than slower tapering (Morin, Bélanger, Bastien, & Vallières, 2005; Parr et al., 2008), while gradual reduction yields better outcomes (Parr et al., 2008).”
Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines
Kales, A., Manfredi, R. L., Vgontzas, A. N., Bixler, E. O., Vela-Bueno, A., & Fee, E. C. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.55 · Cited by 90 · cited 1×
“…are less likely to cause tolerance and withdrawal due to shorter action and once-daily use (meaning receptors have drug-free periods every day), however, dependence, and withdrawal still commonly occur (Nice, 2004; Pollmann et al., 2015) even after brief or intermittent use (Kales et al., 1991).”
Drug discontinuation effects are part of the pharmacology of a drug
Reidenberg, M. M. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183285 · Cited by 82 · cited 1×
“…hours, with some exceptions including commonly prescribed drugs like diazepam and clonazepam) may suggest that dose reductions could be made every few days, dose reduction intervals are better guided by the time needed for neuroadaptations to resolve rather than drug elimination (Reidenberg, 2011).”
Benzodiazepine dependence: Focus on withdrawal syndrome
Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A. A., Vennat, B., Llorca, P.-M., & Eschalier, A. (2009) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2009.07.001 · Cited by 79 · cited 1×
“…underactivity of inhibitory GABA activity, and its downstream effects, during benzodiazepine dose reduction likely cause withdrawal symptoms (Authier et al., 2009), supported by findings that administration of flumazenil – a short-acting selective GABA-A antagonist – induces rapid-onset…”
The Dose Effects of Zolpidem on the Sleep of Healthy Normals
Merlotti, L. A., Roehrs, T., Koshorek, G., Zorick, F. J., Lamphere, J. K., & Roth, T. G. (1989) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198902000-00003 · Cited by 79 · cited 1×
“…humans, hyperbolic relationships occur between benzodiazepine dose and saccadic slowing/sedation (Hommer et al., 1986), zolpidem ’ s effects on sleep (Merlotti et al., 1989) (Figure 3d), diazepam ’ s impact on cortisol and growth hormone (Hommer et al., 1986) and delirium risk in critically ill…”
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77 · cited 3×
“The final dose before complete cessation was generally 25% or 50% of the original dose, when reported, in these studies (Pollmann et al., 2015), with some implying a final dose of 5% – 10% of the original dose (Brandt et al., 2024).”
Self-citationFramer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73 · cited 4×
“Guidance for therapists advises suspending usual assumptions about distress origins during withdrawal (Guy et al., 2019), as severe affective symptoms may be misdiagnosed as primary mental disorders by clinicians unfamiliar with the process (Framer, 2021).”
InfluentialSelf-citationCantopher, T., Olivieri, S., Cleave, N., & Edwards, J. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.3.406 · Cited by 67
Cheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66 · cited 4×
“The physiological mechanisms of benzodiazepine tolerance and adaptation remain uncertain, with mixed findings on reduced number or sensitivity of GABA-A receptors (Cheng et al., 2018).”
InfluentialDrug Binding and Solubility in Milk
Macheras, P. E., Koupparis, M. Α., & Antimisiaris, S. G. (1990) · Pharmaceutical Research · doi:10.1023/a:1015881103340 · Cited by 63 · cited 1×
“Some use full-fat milk for an emulsion (greater fat solubility) (Macheras, Koupparis, & Antimisiaris, 1990; White & Bradnam, 2015), also taken immediately.”
Why are benzodiazepines not yet controlled substances?
Moore, N., Pariente, A., & Bégaud, B. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2190 · Cited by 62 · cited 1×
“The benzodiazepine withdrawal syndrome (Brunner et al., 2025; Cosci & Chouinard, 2020; Ng et al., 2018; Sokya, 2017) Psychological Medicine psychiatric disorder, thereby perpetuating unnecessary long-term treatment (Markota, Rummans, Bostwick, & Lapid, 2016; Moore, Pariente, & Begaud, 2015).”
The Pharmacology and Mechanism of Action of Zolpidem
Sanger, D. J., & Depoortere, H. (1998) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1998.tb00074.x · Cited by 58 · cited 1×
“Z-drugs display hyperbolic effects on locomotion, seizure threshold, muscle relaxation, and ataxia in mice (Sanger & Depoortere, 1998).”
Cloos, J.-M., Bocquet, V., Rolland-Portal, I., Koch, P., & Chouinard, G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000434755 · Cited by 57 · cited 2×
“The 1980s and 1990s also saw regulatory restrictions for certain benzodiazepines (triazolam in particular) in Europe, Hong Kong, and the United States (Cloos et al., 2015).”
Atack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52 · cited 1×
“GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models (Berezhnoy et al., 2008; Wongsamitkul et al., 2017), including recombinant human GABA-A receptors (Atack, 2009) (Figure 3a).”
α subunits in GABAA receptors are dispensable for GABA and diazepam action
Wongsamitkul, N., Maldifassi, M. C., Simeone, X., Baur, R., Ernst, M., & Sigel, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-15628-7 · Cited by 51 · cited 1×
“GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models (Berezhnoy et al., 2008; Wongsamitkul et al., 2017), including recombinant human GABA-A receptors (Atack, 2009) (Figure 3a).”
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Benavides, J., Peny, B., Durand, A., Arbilla, S., & Scatton, B. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10428-x · Cited by 50
Tapering antipsychotic treatment
Horowitz, M. A., Murray, R. M., & Taylor, D. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2166 · Cited by 49 · cited 2×
“…higher risk patients in antidepressant tapering guidelines in Australia and Canada, based on the biological plausibility of this approach and emerging empirical evidence(Horowitz & Wilcock, 2022; Horowitz et al., 2021; Horowitz & Taylor, 2021; Jauca, n.d.; NICE, 2022; Therapeutic Guidelines, 2025).”
Self-citationEffect of Various Antiepileptic Drugs in Zebrafish PTZ-Seizure Model.
(2014) · Europe PMC (PubMed Central) · Cited by 46
A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users
Mintzer, M. Z., Stoller, K. B., & Griffiths, R. R. (1999) · Psychopharmacology · doi:10.1007/s002130051161 · Cited by 45 · cited 1×
“…and its downstream effects, during benzodiazepine dose reduction likely cause withdrawal symptoms (Authier et al., 2009), supported by findings that administration of flumazenil – a short-acting selective GABA-A antagonist – induces rapid-onset withdrawal (Mintzer, Stoller, & Griffiths, 1999).”
Liebrenz, M., Gehring, M.-T., Buadze, A., & Caflisch, C. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0493-y · Cited by 41 · cited 1×
“Patients also experience the withdrawal process as a difficult, complicated, and highly unpredictable process (Liebrenz, Gehring, Buadze, & Caflisch, 2015), some reporting that benzodiazepines are harder to discontinue than opioids because of the withdrawal symptoms (Liebrenz et al., 2015).”
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285584 · Cited by 38 · cited 1×
“…Induced Neurological Dysfunction ’ (BIND) as more appropriate, recognizing that such protracted symptoms often do not respond to re-instatement (Ritvo et al., 2023; Shade et al., 2025), like similar post-cessation-induced neurological dysfunction seen from other classes of psychiatric…”
Self-citationBrouillet, E., Chavoix, C., Bottlaender, M., Khalili-Varasteh, M., Hantraye, P., Fournier, D., Dodd, R. H., & Mazière, M. (1991) · Brain Research · doi:10.1016/0006-8993(91)90131-e · Cited by 37 · cited 3×
“This table, based on the E max equation of best fit derived from the data in Brouillet et al. (1991), after conversion to human equivalent dosage (Nair & Jacob, 2016”
Atack, J. R., Wong, D. F., Fryer, T. D., Ryan, C., Sanabria, S., Zhou, Y., Dannals, R. F., Eng, W.-S., Gibson, R. E., Burns, H. D., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157909 · Cited by 36 · cited 1×
“…data used to model the dose-occupancy curve come from non-human primates rather than humans; while receptor pharmacology is broadly comparable, species differences in subunit composition, distribution, and pharmacokinetics may exist (Atack et al., 2010; Friedman, Redmond, & Greenblatt, 1991).”
The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria?
Higgitt, A., Fonagy, P., Toone, B., & Shine, P. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb01375.x · Cited by 35 · cited 1×
“Withdrawal symptoms can last for many months and sometimes years (Ashton, 1987, 2005; Barker, Greenwood, Jackson, & Crowe, 2004; Higgitt, Fonagy, Toone, & Shine, 1990), and meta-analysis shows cognitive effects after long-term use lasting over six months (Barker et al., 2004).”
Pharmacodynamic principles and the time course of delayed and cumulative drug effects
Holford, N. (2018) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2018.26.2.56 · Cited by 35 · cited 4×
“PET scanning, using the radioligand [ 11 C]flumazenil in non-human primates (Figure 2a), allows visualization of this hyperbolic relationship (Atkins & Nimmo, 1975; Brouillet et al., 1991; Holford, 2018).”
InfluentialDeprescribing antipsychotics: a guide for clinicians
Gupta, S., Cahill, J. D., & Miller, R. (2018) · BJPsych Advances · doi:10.1192/bja.2018.2 · Cited by 35
Schmid, L., Bottlaender, M., Fuseau, C., Fournier, D., Brouillet, E., & Mazière, M. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65041880.x · Cited by 33 · cited 1×
“Many immediate-release, non – enteric-coated tablets can be crushed and dispersed in water without major (Nair & Jacob, 2016; Schmid et al., 1995) Zopiclone 7.5 mg 5 – 6 3.75 mg, 7.5 mg N/A 1.4 (Benavides et al., 1992; Nair & Jacob, 2016) a -”
InfluentialA pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal
Lader, M. H., & Morton, S. V. (1992) · Journal of Psychopharmacology · doi:10.1177/026988119200600303 · Cited by 33 · cited 1×
“Although not well understood, the rate of this reversal varies between individuals and with exposure duration, perhaps explaining withdrawal durations from weeks to years (Ashton, 1995; Lader & Morton, 1992).”
Horowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33 · cited 1×
“…higher risk patients in antidepressant tapering guidelines in Australia and Canada, based on the biological plausibility of this approach and emerging empirical evidence(Horowitz & Wilcock, 2022; Horowitz et al., 2021; Horowitz & Taylor, 2021; Jauca, n.d.; NICE, 2022; Therapeutic Guidelines, 2025).”
Self-citationProtracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome
Ashton, H. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950301-11 · Cited by 32 · cited 1×
“Although not well understood, the rate of this reversal varies between individuals and with exposure duration, perhaps explaining withdrawal durations from weeks to years (Ashton, 1995; Lader & Morton, 1992).”
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Conn, D. K., Hogan, D. B., Amdam, L., Cassidy, K.-L., Cordell, P., Frank, C., Gardner, D., Goldhar, M., Ho, J. M.-W., Kitamura, C., et al. (2020) · Canadian Geriatrics Journal · doi:10.5770/cgj.23.419 · Cited by 32 · cited 1×
“…clinical guidelines recommend that benzodiazepines and z-drugs should be used only for acute situations, and not for longer than 2 – 4 weeks, to avoid the risk of dependence and withdrawal (Conn et al., 2020; Kaiser Permanente, 2019; National Institute for Health and Clinical Excellence, 2011).”
Review: Adjunctive pharmacologic approaches for benzodiazepine tapers
Welsh, J. W., Tretyak, V., McHugh, R. K., Weiss, R. D., & Bogunovic, O. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.028 · Cited by 31 · cited 1×
“…and the ASAM panel concluded ‘ After carefully considering existing evidence on various pharmacological interventions … no single medication had enough data to support recommending it ’ (p. 61) (Brunner et al., 2025), consistent with other analyses (Baandrup et al., 2018; Welsh et al., 2018).”
Tapering antipsychotic medication: practical considerations
Horowitz, M. A., Moncrieff, J., de Haan, L., Bogers, J. P. A. M., Gangadin, S. S., Kikkert, M., Veling, W., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721003299 · Cited by 30
Self-citationA Guide to Benzodiazepine Selection. Part I: Pharmacological Aspects *
Teboul, E., & Chouinard, G. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500811 · Cited by 28 · cited 3×
“Withdrawal arises from both pharmacokinetic and pharmaco-dynamic adaptations and so withdrawal risk varies between benzo-diazepines according to half-life, potency, lipophilicity, receptor affinity, and the presence of active metabolites (Shapiro, 2025; Teboul & Chouinard, 1990, 1991).”
Kleven, M. S., & Koek, W. (1999) · Psychopharmacology · doi:10.1007/s002130050826 · Cited by 26 · cited 1×
“Anxiolytic effects increase hyperbolically in pigeons (Kleven & Koek, 1999), rats (Dubinsky et al., 2002), and non-human primates (Rowlett et al., 2005) (Figure 3c).”
How to reduce and stop psychiatric medication
Horowitz, M. A., & Taylor, D. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.001 · Cited by 26
Self-citationA Guide to Benzodiazepine Selection. Part II: Clinical Aspects
Teboul, E., & Chouinard, G. (1991) · The Canadian Journal of Psychiatry · doi:10.1177/070674379103600117 · Cited by 25 · cited 5×
“However, clonazepam ’ s favorable pharmacokinetic profile (longer alpha and beta half-lives) lends itself to less plasma fluctuations and inter-dose withdrawal anxiety despite its high potency (Teboul & Chouinard, 1991).”
InfluentialAshton, H. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0013 · Cited by 25
Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys
Friedman, H., Redmond, D. E., & Greenblatt, D. J. (1991) · Psychopharmacology · doi:10.1007/bf02244562 · Cited by 24 · cited 1×
“…data used to model the dose-occupancy curve come from non-human primates rather than humans; while receptor pharmacology is broadly comparable, species differences in subunit composition, distribution, and pharmacokinetics may exist (Atack et al., 2010; Friedman, Redmond, & Greenblatt, 1991).”
Neurobiology and principles of addiction and tolerance
Turton, S., & Lingford-Hughes, A. (2016) · Medicine · doi:10.1016/j.mpmed.2016.09.007 · Cited by 24 · cited 2×
“Adaptations to a substance cause tolerance during exposure and predict withdrawal when the substance is removed and these adaptations act unopposed (Turton & Lingford-Hughes, 2016).”
Cooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23 · cited 1×
“A survey of specialized deprescribing clinics around the world report using hyperbolic tapering as their main approach to safely stopping psychiatric drugs, including benzodiazepines (Cooper et al., 2023).”
Self-citationPharmacological Properties of DOV 315,090, an ocinaplon metabolite
Berezhnoy, D., Gravielle, M. C., Downing, S., Kostakis, E., Basile, A. S., Skolnick, P., Gibbs, T. T., & Farb, D. H. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-11 · Cited by 18 · cited 1×
“GABA-gated currents increase hyperbolically with increasing diazepam concentrations in cellular models (Berezhnoy et al., 2008; Wongsamitkul et al., 2017), including recombinant human GABA-A receptors (Atack, 2009) (Figure 3a).”
Bottlaender, M., Brouillet, E., Varastet, M., Le Breton, C., Schmid, L., Fuseau, C., Sitbon, R., Crouzel, C., & Mazière, M. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031102.x · Cited by 17 · cited 1×
“Seizure threshold shows a hyperbolic relationship to dose in zebrafish (Gupta, Kho-bragade, & Shingatgeri, 2014), rats (Kapur & Macdonald, 1997), and non-human primates (Bottlaender et al., 1994) (Figure 3b).”
Addiction and physical dependence are not the same thing
Horowitz, M. A., & Taylor, D. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00230-4 · Cited by 16 · cited 1×
“…physical dependence – neuroadaptation causing withdrawal on reduction – from addiction, which also involves psychological dependence (including compulsion, craving, and other behavioral and cognitive components not seen in physical dependence alone) (Horowitz & Taylor, 2023; O ’ Brien, 2011).”
Self-citationThe Trans-Pacific Partnership (TPP) Agreement
Amari, A. (2016) · Asia-Pacific Review · doi:10.1080/13439006.2016.1195948 · Cited by 16
Eserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115537 · Cited by 15 · cited 1×
“Consistent with this, a recent systematic review of tapering strategies for psychiatric drugs, including benzodiazepines, concluded that ‘ hyperbolic tapering … appears to be the most promising strategy for psychiatric drug discontinuation ’ (Eserian et al., 2023).”
Basińska-Szafrańska, A. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03205-x · Cited by 12
Lynch, T., Ryan, C., Huff, C., Foster, D. E., & Cadogan, C. (2024) · Health Expectations · doi:10.1111/hex.13962 · Cited by 11 · cited 1×
“…The Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024). a These doses are estimates based on averages, with limitations outlined in the text. withdrawal symptoms were linked to greater success (Lynch et al., 2024).”
Self-citationLynch, T., Ryan, C. A., Bradley, C., Foster, D. E., Huff, C., Hutchinson, S. J., Lamberson, N., Lynch, L., & Cadogan, C. A. (2022) · Health Expectations · doi:10.1111/hex.13547 · Cited by 9 · cited 1×
“…has been recommended as an effective intervention, typically delivered by individuals with lived experience of benzodiazepine tapering, either in one-on-one or in group settings, in-person or virtually, important for normalization, encouragement, and identification (Lynch et al., 2022; NICE, 2022).”
Self-citationBenzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse
Horowitz, M. A., & Davies, J. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542437 · Cited by 7 · cited 1×
“…Dysfunction ’ (BIND) as more appropriate, recognizing that such protracted symptoms often do not respond to re-instatement (Ritvo et al., 2023; Shade et al., 2025), like similar post-cessation-induced neurological dysfunction seen from other classes of psychiatric drugs (Horowitz & Davies, 2024).”
Self-citationClearing the confounding confusion: Benzodiazepines and the risk of dementia?
Friesen, K. J., Falk, J., Kuo, I. F., Singer, A. G., & Bugden, S. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105850 · Cited by 7 · cited 1×
“There is mixed evidence about the connection between benzodiazepine use and increased risk of dementia (De Gage et al., 2014; Friesen et al., 2025; Gray et al., 2016) and increased mortality (Ng, Le Couteur, & Hilmer, 2018; Patorno et al., 2017).”
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025) · PLOS One · doi:10.1371/journal.pone.0330277 · Cited by 7 · cited 2×
“…Dysfunction ’ (BIND) as more appropriate, recognizing that such protracted symptoms often do not respond to re-instatement (Ritvo et al., 2023; Shade et al., 2025), like similar post-cessation-induced neurological dysfunction seen from other classes of psychiatric drugs (Horowitz &…”
Self-citation
Research works printed but not linked: 11
- White, 2015, Handbook of drug administration via enteral feeding tubes (third)
- Dhaliwal, 2025, Diazepam
- Parsons, 2012, Dependence on benzodiazepines or Z-drugs: Having that conversation, The Pharmaceutical Journal, 289, 399
- Dubinsky, 2002, Nonbenzodiazepine anxiolytic, Pharmacology, 303, 777
- 2018, MOC guidelines for tablet crushing in patients with swallowing difficulties
- Guy, 2019, Guidance for psychological therapists: Enabling conversations with clients taking or withdrawing from prescribed psychiatric drugs
- Shapiro, 2025, The psychopharmacology blue book
- 2004, Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
- Root, 2011, Pharmaceutical issues when crushing, opening or splitting Oral dosage forms, Royal Pharmaceutical Society, 1, 1
- Horowitz, 2024, The Maudsley deprescribing guidelines in psychiatry: Antidepressants, benzodiazepines, Gabapentinoids and Z-drugs
- Harriman, 2014, Deprescribing medication for frail elderly patients: Survey of Vancouver family physicians, Canadian Family Physician Medecin de famille canadien, 60, S16
Metadata
- Authors
- Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D.
- Affiliations
- North East London NHS Foundation Trust (GB)
- Benzodiazepine Information Coalition
- University of Manitoba (CA)
- Psychotropic Deprescribing Council
- University of California, Irvine (US)
- Rigshospitalet (DK)
- Trinity College Dublin (IE)
- University of Colorado Anschutz (US)
- Columbia University (US)
- Corresponding author
- Horowitz, Mark
- ORCID
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2026
- Volume
- 56
- Pages
- e198-e198
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- PMC
- PMC13280687
- OpenAlex
- W7165192235
- Cited by
- 0
- References
- 81
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Psychological Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, Z-drugs, deprescribing, dose reduction, tapering, withdrawal symptoms, physical dependence, chronic drug administration, compounded formulations
- MeSH terms
- Deprescriptions, Drug Tapering, Benzodiazepines, Dose-Response Relationship, Drug, Humans, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.